Speakers at a scientific seminar today said Pfizer’s new anti-Covid drug “Paxlovid” will be a game changer in the treatment of Covid-19 patients with mild to moderate symptoms as it reduces the risks of hospitalisation and death by around 89 percent.
Eskayef Pharmaceuticals yesterday rolled out the world’s first generic version of Pfizer’s Covid pill Paxlovid, offering a highly effective defence against severe illness from the coronavirus in Bangladesh, where the majority of the population remain unvaccinated.